Sue Washer | Chief Executive Officer |
Bill Sullivan | Chief Financial Officer |
Mark Shearman | Chief Scientific Officer |
Theresa Heah | Chief Medical Officer |
Matt Feinsod | Executive Vice President of Global Strategy and Development |
David Knop | Executive Director of Process Development. |
Joe Pantginis | H.C. Wainwright |
Matthew Luchini | BMO Capital Markets |
Jim Birchenough | Wells Fargo |
David Nierengarten | Wedbush Securities |
Yun Zhong | Janney |
Good afternoon, and welcome to AGTC Fourth Quarter and Fiscal Year 2019 Financial Results Conference Call. Today’s call is being recorded.
Before we get started, I would like to remind everyone that during this call AGTC may make forward-looking statements including statements about the Company’s financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors including uncertainties inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of AGTC’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019.
For introductions and opening remarks, I would like to turn the call over to Sue Washer, Chief Executive Officer of AGTC.